Zymeworks ZYME 深 沪

Market-Moving News for November 17th

GOOG: 5% | Alphabet Inc shares are trading higher after Berkshire Hathaway disclosed a new stake in the company. ZYME: 61% | Zymeworks shares are trading higher after the company and its partners reported

11-17 20:23

Earnings Scheduled For November 6, 2025

Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...

11-06 19:12

首款胃癌“国货之光”！石药/康宁杰瑞HER2双抗撬动百亿市场

（来源：求实药社） 2025年9月11日，石药集团与康宁杰瑞共同宣布，其合作开发的HER2双特异性抗体KN026（安尼妥单抗注射液）新药上市申请（NDA）已获中...

09-16 12:05

【天风医药杨松团队|公司点评】百济神州：2025 Q2 利润端大幅超预期，连续两季度 GAAP 利润为正

（来源：一棵大松树） 公司发布2025年半年度主要财务数据，2025H1总收入24.33亿美元，同比增长45%；GAAP净利润和经调整后净利润分...

08-27 12:59

从烧钱到赚钱！“创新药一哥”首次盈利

2025年8月6日，百济神州发布2025年半年度主要财务数据公告：营业总收入175.18亿元人民币，同比增长46.0%；产品收入173.60亿元，同比增长45...

08-13 07:34

百济神州首次实现半年度盈利！泽布替尼销售额破百亿元，后续管线面临激烈竞争

百济神州（688235.SH、06160.HK）终于迎来半年度盈利。8月6日，百济神州公布2025年半年度主要财务数据，公告显示，2025年上半年，百济神州实现...

08-07 20:48

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

Zymeworks' zanidatamab receives conditional approval in China for HER2+ biliary tract cancer, becoming the first and only dual HER2-targeted bispecific antibody approved for this indication. The company is eligible for a $20 million milestone payment and up to $144 million in additional payments, reflecting its global progress in addressing high unmet need in this disease area.

05-30 10:00

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

05-22 21:00

Deep Dive Into Zymeworks Stock: Analyst Perspectives (4 Ratings)

Across the recent three months, 4 analysts have shared their insights on Zymewo...

03-11 05:04

Gangtise投研日报 | 2025-03-10

以下为3月7日热点题材的涨幅表现 制造| 科技（8条） 01. Manus分析师表示，虽然Manus底层接其他大模型，在大模型能力突破上不占优势...

03-10 06:30